Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TFPI-2

TFPI-2

Brief Information

Name:DNA-(apurinic or apyrimidinic site) lyase
Target Synonym:AP endonuclease 1,DNA-(apurinic or apyrimidinic site) lyase,APE1,APEN,REF-1,Apurinic-apyrimidinic endonuclease 1,APEX nuclease,REF1,APEX,APEX1,Apurinic/Apyrimidinic Endodeoxyribonuclease 1,APEX Nuclease (Multifunctional DNA Repair Enzyme) 1,Redox Factor-1,HAP1,APE,APX,APEX Nuclease (Multifunctional DNA Repair Enzyme),Deoxyribonuclease (Apurinic Or Apyrimidinic),Apurinic/Apyrimidinic (Abasic) Endonuclease,AP Endonuclease Class I,Protein REF-1,AP Lyase,APE-1,DNA-(apurinic or apyrimidinic site) end
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TF2-H5227 Human Human TFPI-2 Protein, His Tag
TF2-H5227-structure
TF2-H5227-sds
ACRO Quality

Synonym Name

TFPI2,PP5,REF1

Background

Tissue Factor Pathway Inhibitor 2 (TFPI­2) is also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF­1), is a member of the Kunitz-type serine proteinase inhibitor family, is a structural homologue of tissue factor pathway inhibitor (TFPI). TFPI2 is highly abundant in the full-term placenta and widely expressed in umbilical vein endothelial cells, liver, placenta, heart, pancreas, and maternal serum at advanced pregnancy. TFPI­2 may play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa and has no effect on thrombin. Reduced synthesis of TFPI-2 has been related to numerous pathophysiological processes such as inflammation, angiogenesis, atherosclerosis, retinal degeneration and tumor growth / metastasis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
APX-3330 E-3330; APX-3330 Phase 2 Clinical Eisai Co Ltd Neoplasms; Diabetic macular oedema; Diabetic Retinopathy Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message